Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
08/2003
08/07/2003WO2003064441A2 Oligonucleotides comprising alternating segments and uses thereof
08/07/2003WO2003064425A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003WO2003064423A1 Aza-arylpiperazines
08/07/2003WO2003064411A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
08/07/2003WO2003064404A1 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
08/07/2003WO2003064397A1 Indazole compounds useful as protein kinase inhibitors
08/07/2003WO2003064392A1 Process for the manufacture of hmg-coa reductase inhibitors
08/07/2003WO2003064389A1 Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
08/07/2003WO2003064383A2 Phosphorus-containing compounds & uses thereof
08/07/2003WO2003064376A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps)
08/07/2003WO2003064369A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003WO2003063905A1 Preventives or remedies for immunological diseases
08/07/2003WO2003063894A1 Insulin resistance improving agents
08/07/2003WO2003063892A1 Use of apelin
08/07/2003WO2003063891A1 Compositions and methods for modulating connexin hemichannels
08/07/2003WO2003063875A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003WO2003063874A1 Condensed heterocyclic compounds
08/07/2003WO2003063859A1 Suppression of cartilage degradation via the estrogen receptor
08/07/2003WO2003063853A1 Compositions for lessening mesenteric fat
08/07/2003WO2003063851A1 Composition for pharmaceutical or dietetic use for combating hair loss
08/07/2003WO2003063849A1 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome
08/07/2003WO2003063846A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
08/07/2003WO2003063834A1 Multi-stage oral drug controlled-release system
08/07/2003WO2003063828A1 Jojoba product for reducing weight, blood lipid levels and for the prevention and treatment of cancer
08/07/2003WO2003063821A2 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003WO2003063800A2 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/07/2003WO2003063796A2 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003WO2003063758A2 Bicyclic cb2 cannabinoid receptor ligands
08/07/2003WO2003063608A1 A process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent
08/07/2003WO2003063576A2 Arylsulfonamidobenzylic compounds
08/07/2003WO2003046556A3 Globin biopolymer markers indicative of insulin resistance
08/07/2003WO2003030829A3 Liposome-encapsulated insulin formulations
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2002068476A3 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
08/07/2003WO2002056873A3 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002024222A3 Ligands for g protein coupled receptors and methods of using them
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149296 Such as 3-(4-salicyloylamino)phenoxypropionic acid; noncovalent drug delivery
08/07/2003US20030149277 Triarylimidazole derivatives as cytokine inhibitors
08/07/2003US20030149268 Administering non-steroidal 9-pyrido(3,2-g)quinoline compounds to the mammal for affecting androgen receptor activity
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149111 For therapy of diabetes, hyperglycemia
08/07/2003US20030149110 For use as as neuro-protective agents for therapy of conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine
08/07/2003US20030149108 Linked biaryl compounds
08/07/2003US20030149107 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
08/07/2003US20030149104 Tri-substituted phenyl derivatives and analogues
08/07/2003US20030149101 Administering combination of a cholesterol lowering drug and an angiotensin converting enzyme inhibitor for therapy of atherosclerosis
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149091 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder
08/07/2003US20030149087 For therapy of atherosclerosis, gallstone disease, lipid disorders, obesity or a cardiovascular disorder
08/07/2003US20030149083 For therapy of inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic erythematodes, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis
08/07/2003US20030149073 Cycloalkano-indole and -azaindole derivatives
08/07/2003US20030149071 Pyrido [2,1-a] isoquinoline derivatives
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149044 Succinic acid salts of 5,7,14-triazatetracyclo[10.1.02.11.04,9] -hexadeca-1(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
08/07/2003US20030149043 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
08/07/2003US20030149040 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149027 1,5-benzodiazepine compounds, their production and use
08/07/2003US20030149026 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc.
08/07/2003US20030149020 For therapy or prophylaxis of obesity, type II diabetes, or disorders of the central nervous system
08/07/2003US20030149019 For therapy or prophylaxis of obesity, type II diabetes, or disorders of the central nervous system
08/07/2003US20030149018 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149006 New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148983 Polynucleotide therapy
08/07/2003US20030148974 Antisense modulation of akt-3 expression
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148465 Comprises membrane protein for diagnosis and treatment of atherosclerosis, viral and inflammatory diseases
08/07/2003US20030147979 Ligand for peroxisome proliferator-activated receptor
08/07/2003US20030147952 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
08/07/2003US20030147951 Tablet composition
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147903 ABC transport polynucleotides, polypeptides and antibodies
08/07/2003US20030147889 Administering type 1-interferon antibody, for inhibition of prevention of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis and psoriasis
08/07/2003US20030147862 Administering a colony stimulating factor and/or a nucleic acids encoding the factor; treating a vascular tumor
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2474958A1 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474845A1 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
08/07/2003CA2474788A1 Compositions and methods for modulating connexin hemichannels
08/07/2003CA2474702A1 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474434A1 Condensed heterocyclic compounds
08/07/2003CA2474433A1 Arylsulfonamidobenzylic compounds
08/07/2003CA2474414A1 Oligonucleotides comprising alternating segments and uses thereof
08/07/2003CA2473990A1 Modulation of type ii.beta. phosphoinositide phosphate kinase
08/07/2003CA2473250A1 Fractionation of phytosterol esters in oil
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1333025A1 Cyanopyrrolidine derivatives
08/06/2003EP1333022A2 Compounds containing derivatives of cyclopentane and their use to stimulate skin peeling
08/06/2003EP1332763A1 High-density lipoprotein-cholesterol level elevating agent
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
1 ... 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 ... 1298